Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib

Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder that accounts for 2% of all leukemia. Recent identification of the recurrent V600E BRAF mutation in a majority of HCL patients has led some teams to evaluate the clinical potential of vemurafenib, a BRAF V600 specific inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailleux, Caroline, Robert, Guillaume, Ginet, Clémence, Re, Daniel, Thyss, Antoine, Sudaka, Isabelle, Peyrottes, Isabelle, Hofman, Paul, Auberger, Patrick, Peyrade, Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341463/
https://www.ncbi.nlm.nih.gov/pubmed/25815361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341463/
https://www.ncbi.nlm.nih.gov/pubmed/25815361

Ejemplares similares